Standout Papers

Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results fr... 2023 2026 2024169
  1. Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial (2023)
    Kausik K. Ray, Frank L.J. Visseren et al. The Lancet Diabetes & Endocrinology

Immediate Impact

37 standout
Sub-graph 1 of 17

Citing Papers

Emerging Delivery Systems for Enabling Precision Nucleic Acid Therapeutics
2025 Standout
Advances in nanoparticles in targeted drug delivery–A review
2025 Standout
3 intermediate papers

Works of Zsolt Talloczy being referenced

Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial
2023 Standout

Author Peers

Author Last Decade Papers Cites
Zsolt Talloczy 291 188 134 250 11 558
P. Pfister 46 329 40 102 17 543
Youssef Elnabawi 114 110 19 313 15 532
Khalid Almutairi 358 36 102 100 15 581
Poorya Amini 21 165 54 324 9 633
Jamie Robertson 297 66 76 151 7 551
Daniele Compagnone 315 35 181 99 11 502
Elyssa Ott 54 158 28 193 14 475
Spyros N. Nikas 328 45 107 118 16 496
E. Roeseler 52 518 52 91 14 578
Craig W. Wiesenhutter 149 91 49 141 16 534

All Works

Loading papers...

Rankless by CCL
2026